EA026419B1 - Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона - Google Patents

Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона Download PDF

Info

Publication number
EA026419B1
EA026419B1 EA201290865A EA201290865A EA026419B1 EA 026419 B1 EA026419 B1 EA 026419B1 EA 201290865 A EA201290865 A EA 201290865A EA 201290865 A EA201290865 A EA 201290865A EA 026419 B1 EA026419 B1 EA 026419B1
Authority
EA
Eurasian Patent Office
Prior art keywords
carbidopa
entacapone
levodopa
dosage form
amount
Prior art date
Application number
EA201290865A
Other languages
English (en)
Russian (ru)
Other versions
EA201290865A1 (ru
Inventor
Юха Роуру
Микко Куоппамяки
Юха Эллмен
Пекка Мяннисте
Original Assignee
Орион Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орион Корпорейшн filed Critical Орион Корпорейшн
Publication of EA201290865A1 publication Critical patent/EA201290865A1/ru
Publication of EA026419B1 publication Critical patent/EA026419B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201290865A 2010-03-04 2011-03-03 Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона EA026419B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31039810P 2010-03-04 2010-03-04
US41282110P 2010-11-12 2010-11-12
US201161438416P 2011-02-01 2011-02-01
PCT/FI2011/000013 WO2011107653A2 (en) 2010-03-04 2011-03-03 Method for treating parkinson's disease

Publications (2)

Publication Number Publication Date
EA201290865A1 EA201290865A1 (ru) 2013-02-28
EA026419B1 true EA026419B1 (ru) 2017-04-28

Family

ID=44065577

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290865A EA026419B1 (ru) 2010-03-04 2011-03-03 Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона

Country Status (14)

Country Link
US (4) US20130137729A1 (enExample)
EP (1) EP2542220B1 (enExample)
JP (2) JP5774610B2 (enExample)
KR (1) KR101868326B1 (enExample)
CN (1) CN102781424B (enExample)
AU (1) AU2011222856B2 (enExample)
BR (1) BR112012018256A8 (enExample)
CA (1) CA2784819C (enExample)
EA (1) EA026419B1 (enExample)
ES (1) ES2614179T3 (enExample)
IL (1) IL221744A (enExample)
MX (1) MX336187B (enExample)
WO (1) WO2011107653A2 (enExample)
ZA (1) ZA201205836B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616377C (en) 2005-07-26 2014-04-01 David Alexander Learmonth Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
TW200942531A (en) 2008-03-17 2009-10-16 Bial Portela & Companhia S A Crystal forms of a nitrocatechol
KR20210009441A (ko) 2009-04-01 2021-01-26 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
EP2542220B1 (en) * 2010-03-04 2016-11-02 Orion Corporation Use of levodopa, carbidopa and entacapone for treating parkinson's disease
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
PT2791134T (pt) 2011-12-13 2019-12-18 BIAL PORTELA & Cª S A Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
CN104884064A (zh) * 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
US9642810B2 (en) 2013-03-15 2017-05-09 Mylan Inc. Formulation containing carbidopa, levodopa, and entacapone
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
CN108349993A (zh) * 2015-08-27 2018-07-31 普雷克斯顿医疗股份公司 用于左旋多巴诱导的运动障碍疗法的脑-穿透剂色酮肟衍生物
HRP20251502T1 (hr) * 2018-03-23 2026-02-13 Lobsor Pharmaceuticals Aktiebolag Kontinuirana primjena farmaceutskog pripravka za liječenje neurodegenerativnih poremećaja
EP3880210A1 (en) 2018-11-15 2021-09-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
CN112741808B (zh) * 2019-10-29 2024-02-06 南京济群医药科技股份有限公司 一种提高含盐酸苄丝肼口服固体组合物稳定性的方法
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
US20230181493A1 (en) * 2020-04-10 2023-06-15 Senda Biosciences, Inc. Biomarkers related to parkinson's disease and methods of using the same
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017201A1 (en) * 1999-06-30 2003-01-23 Matti Virkki Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
WO2010020969A1 (en) * 2008-08-22 2010-02-25 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
WO2010020970A1 (en) * 2008-08-22 2010-02-25 Wockhardt Research Centre Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
WO2010027340A1 (en) * 2008-09-03 2010-03-11 Dr. F. Frik Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions composing entakapon, levodopa and karbidoba

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3462536A (en) 1960-07-22 1969-08-19 Merck & Co Inc Method of inhibiting decarboxylase
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
US20080076825A1 (en) 2003-12-31 2008-03-27 Thomas Bader Novel Crystalline Forms of Entacapone and Production Thereof
JP4781352B2 (ja) 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
EP2335696A1 (en) 2005-06-08 2011-06-22 Orion Corporation An entacapone-containing oral dosage form
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
CA2616377C (en) * 2005-07-26 2014-04-01 David Alexander Learmonth Nitrocatechol derivatives as comt inhibitors
AU2006322051B2 (en) 2005-12-05 2011-09-29 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
EP2104424A4 (en) 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
CN101959504A (zh) 2008-02-28 2011-01-26 比艾尔-坡特拉有限公司 用于难溶性药物的药物组合物
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
EP2542220B1 (en) * 2010-03-04 2016-11-02 Orion Corporation Use of levodopa, carbidopa and entacapone for treating parkinson's disease
JP5551001B2 (ja) 2010-06-22 2014-07-16 株式会社Ｐｆｕ 摩擦係数推定装置および摩擦係数推定方法
JP2015006373A (ja) * 2014-07-14 2015-01-15 株式会社大都技研 遊技台

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017201A1 (en) * 1999-06-30 2003-01-23 Matti Virkki Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
WO2010020969A1 (en) * 2008-08-22 2010-02-25 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
WO2010020970A1 (en) * 2008-08-22 2010-02-25 Wockhardt Research Centre Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
WO2010027340A1 (en) * 2008-09-03 2010-03-11 Dr. F. Frik Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions composing entakapon, levodopa and karbidoba

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARLA EGGERT ; ÖRJAN SKOGAR ; KHALED AMAR ; LIISA LUOTONEN ; MIKKO KUOPPAMäKI ; MIKA LEINONEN ; HELENA NISSINEN ; WOLFGANG OERTE: "Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study", JOURNAL OF NEURAL TRANSMISSION ; BASIC NEUROSCIENCES, GENETICS AND IMMUNOLOGY, PARKINSON'S DISEASE AND ALLIED CONDITIONS, ALZHEIMER'S DISEASE AND ADOLESCENT PSYCHIATRY RELATED DISORDERS, BIOLOGICAL PSYCHIATRY, BIOLOGICAL CHILD AND ADOLESCENT PSYCHIAT, vol. 117, no. 3, 15 December 2009 (2009-12-15), Vi, pages 333 - 342, XP019805095, ISSN: 1435-1463 *

Also Published As

Publication number Publication date
EA201290865A1 (ru) 2013-02-28
ES2614179T3 (es) 2017-05-30
AU2011222856B2 (en) 2015-10-15
EP2542220B1 (en) 2016-11-02
ZA201205836B (en) 2014-01-29
US20210085635A1 (en) 2021-03-25
JP2015180644A (ja) 2015-10-15
KR20130006638A (ko) 2013-01-17
JP2013521263A (ja) 2013-06-10
WO2011107653A8 (en) 2012-08-02
HK1177896A1 (zh) 2013-08-30
US20150150839A1 (en) 2015-06-04
KR101868326B1 (ko) 2018-06-19
BR112012018256A8 (pt) 2017-12-19
MX336187B (es) 2016-01-07
US12521363B2 (en) 2026-01-13
CN102781424B (zh) 2016-03-30
IL221744A (en) 2016-11-30
US20240050394A1 (en) 2024-02-15
JP5774610B2 (ja) 2015-09-09
EP2542220A2 (en) 2013-01-09
CN102781424A (zh) 2012-11-14
US11771675B2 (en) 2023-10-03
CA2784819A1 (en) 2011-09-09
BR112012018256A2 (enExample) 2011-09-09
CA2784819C (en) 2018-02-13
WO2011107653A2 (en) 2011-09-09
WO2011107653A3 (en) 2011-11-03
US20130137729A1 (en) 2013-05-30
US10857120B2 (en) 2020-12-08
AU2011222856A1 (en) 2012-07-26
MX2012010161A (es) 2012-10-03

Similar Documents

Publication Publication Date Title
EA026419B1 (ru) Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
JP6328205B2 (ja) レボドパの放出制御製剤及びその使用
CN109646404B (zh) 葡萄糖激酶激活剂的口服制剂及其制备方法
JP5864409B2 (ja) ニトロカテコール誘導体を含む医薬製剤及びその製造方法
WO2013110085A1 (en) Oral dosage forms for delivering metformin and sitagliptin
CA2987177A1 (en) Once-daily oral pharmaceutical composition of isotretinoin
JP2007509146A (ja) レボドーパの持続効果のための組成物及び投与形
KR20210109480A (ko) 벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물
TWI608849B (zh) 可調控釋放度之高載藥量之醫藥組合物及其製備方法
KR20200077956A (ko) 티카그렐러 또는 이의 염을 함유하는 서방형 약제학적 조성물
JP2022541948A (ja) エソメプラゾール及び炭酸水素ナトリウムを含む安定した薬学的組成物
ES2804348T3 (es) Formulaciones de liberación controlada de levodopa y usos de las mismas
HK1177896B (en) Use of levodopa, carbidopa and entacapone for treating parkinson's disease
TWI505841B (zh) 治療睡眠障礙之控釋調配物
HK40007318B (en) Oral formulation of glucokinase activators and preparation method thereof
HK40007318A (en) Oral formulation of glucokinase activators and preparation method thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU